acalabrutinib + dexamethasone

**Acalabrutinib + dexamethasone** is a combination of two pharmaceutical drugs: acalabrutinib, a selective Bruton tyrosine kinase (BTK) inhibitor, and dexamethasone, a synthetic glucocorticoid corticosteroid. - **Acalabrutinib** acts by covalently binding to and inhibiting Bruton tyrosine kinase, which is essential for B-cell receptor signaling. This inhibition impairs malignant B-cell proliferation and survival, making acalabrutinib a targeted therapy for B-cell malignancies including mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL)[2][1][5]. - **Dexamethasone** exerts its effects by binding to and agonizing the glucocorticoid receptor, which leads to anti-inflammatory and immunosuppressive effects. It is used for a variety of inflammatory, autoimmune, and malignancy-associated conditions. This exact combination (acalabrutinib + dexamethasone) is not established as a unique therapeutic regimen in major guidelines or approved indications. While acalabrutinib is formally combined with other agents (e.g., bendamustine and rituximab) for MCL, dexamethasone is not a standard partner[1][4]. There is a pharmacokinetic interaction in which dexamethasone (a CYP3A inducer) may reduce acalabrutinib plasma levels, and direct concurrent use is generally cautioned against unless the benefit outweighs the risk[3]. No unique combination product or new entity exists with acalabrutinib and dexamethasone as the sole actives.